# KEYNOTE-B61 (NCT04704219)

> Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04704219
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Renal Cell Carcinoma
- Interventions: Pembrolizumab; Lenvatinib
- Enrollment: 160
- Primary outcome: Objective Response Rate (ORR)

## Commentary we found

- X threads: 14
- YouTube: 13
- Podcasts: 7

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=keynote-b61-nct04704219

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04704219", "email": "<work email>"}; the inbox owner confirms by the emailed link.